BD Achieves Landmark with First Phasix™ Hernia Prevention Procedure in Greece and 85% Enrollment in U.S. Trial

BD Marks a Major Milestone in Hernia Prevention

BD (Becton, Dickinson and Company), a prominent leader in global medical technology, has reached an impressive milestone with the initiation of its first Phasix™ Mesh laparotomy reinforcement procedure performed in Greece. This procedure follows the product's expanded approval for prophylactic use in Europe, making it the first widely recognized hernia mesh solution intended for open, high-risk surgical procedures across the European Union.

The successful operation took place at the George Papanikolaou General Hospital located in Thessaloniki, one of Northern Greece's largest healthcare facilities. The procedure was effectively carried out by general surgeon and Associate Professor, Ioannidis Orestis, on a 63-year-old male patient who faced various risk factors. The patient underwent a sigmoidectomy, and to proactively mitigate the risk of future hernias, a Phasix™ Mesh (08 x 30 cm) was utilized at the incision site.

In parallel with this achievement, BD is conducting the PREVENT multicenter randomized controlled trial across various sites in Europe and the United States, where over 85% of the targeted participant population has been treated. The trial is expected to conclude its enrollment in 2026 and aims to provide valuable clinical data that supports the use of prophylactic bioabsorbable mesh in reducing the occurrence of incisional hernias. Additionally, this evidence will bolster the company's submission for a premarket approval (PMA) in the United States for preventing incisional hernias.

Rian Seger, the worldwide president of BD's Surgery business, commented, "Incisional hernias impact up to 30% of patients post-abdominal surgery and impose significant costs on healthcare systems, amounting to billions annually. With Phasix™ Mesh, our goal extends beyond simply repairing hernias; we are revolutionizing their prevention. This achievement underscores our dedication to enhancing long-term patient outcomes."

Recent data from the U.K. highlights that patients who undergo repairs for incisional hernias typically face an average cost of £23,148, which is nearly twice that of individuals who do not need such interventions. By implementing preventive strategies, healthcare systems may drastically decrease these expenses while enhancing the quality of life for patients.

Phasix™ Mesh has been granted CE marking approval for prophylactic use and saw the launch of three new sizes in 2025. It is now registered in the U.K. and available throughout Europe, heralding a groundbreaking transition in surgical practices intended to bolster patient safety and enhance efficiency during procedures.

However, it is important to note that Phasix™ Mesh is not currently approved for use in preventing hernias within the United States.

About BD

BD stands as one of the largest global medical technology firms, committed to propelling advancements in healthcare by facilitating medical discoveries, diagnostic improvements, and the enhancement of care delivery. The company prides itself on collaborating closely with healthcare heroes, developing innovative technologies, and comprehensive solutions that advance clinical therapy and processes alike. With a dedicated workforce of more than 70,000, BD is passionate about enhancing the safety and efficiency of healthcare providers' delivery methods, enabling laboratory experts to diagnose diseases accurately, and empowering researchers to innovate for future healthcare needs. With a presence in nearly every country, BD partners globally to confront some of the most pressing health challenges, ensuring an impactful enhancement in healthcare outcomes, cost reduction, efficiency improvement, safety increase, and expanded access to healthcare services. For further details about BD, visit bd.com.